Aytu Bioscience, Inc.

Description

• Aytu BioScience is a specialty pharmaceutical company focused on commercializing novel products in the field of urology. Aytu is initially concentrating on hypogonadism (low testosterone), prostate cancer, urinary tract infections, and male infertility and plans to expand into other urological indications for which there are significant medical needs. The company has three marketed, FDA-approved products that fill distinct patient needs in significant urological conditions. The company currently markets Natesto, the only FDA-approved nasally-administered testosterone, which is indicated for the treatment of hypogonadism. Aytu also markets ProstaScint, an FDA-approved radioimaging agent indicated to detect prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The company also markets Primsol, an FDA-approved oral antibiotic indicated for the treatment of uncomplicated urinary tract infections. Primsol is the only FDA-approved trimethoprim-only oral solution. Aytu is also conducting late-stage clinical trials with the companys MiOXSYS system, a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.
• 

  Headquarters:373 Inverness Parkway Suite 206, Englewood, Colorado, United States

  More
• 

  Phone Number: +1 720-437-6580

• 

  Website: https://www.aytubio.com

• 

  Employees:72

• 

  Revenue:$10 - 50M

• 

  Legal Name:Aytu Bioscience, Inc.

• Aytu Bioscience, Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 541714  |

  Show More